Search

Islatravir

[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for … [L56141] This formulation represents a significant advance in long-acting oral therapy due to islatravir's exceptionally long intracellular half-life, which allows for extremely low dosing.

Metaxalone

Metaxalone is associated with few side effects and is available as a 800 mg scored tablet. … Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions.

Segesterone acetate

Due to its rapid hepatic metabolism, segesterone acetate must be administered parenterally [A37090]. … In animal studies, segesterone acetate was shown to be one of the most potent progestins [A37090]. It mediates progestational activity 100 times higher than that of [progesterone] [A37092].

Phenylpropanolamine

Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.

Solcoseryl

Bemotrizinol

Bemotrizinol, or bis-ethylhexyloxyphenol methoxyphenyl triazine, is an organic UV filter found in over-the-counter sunscreen products. It primarily absorbs UV-A rays. … Compared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212].

Tubocurarine

[A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen. … [A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048]

Mobocertinib

NSCLC in patients with _EGFR_ exon 20 insertion mutations who have failed previous therapies. … [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations

Calaspargase pegol

Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation.

Fenticonazole

Fenticonazole has a broad spectrum of antimycotic activity against dermatophytes and yeasts.